Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2008

View Archived Issues

Recent patents describe novel antidiabetic agents

New antiobesity agents described in recent Schering-Plough patent

Recent AstraZeneca and Abbott patents report novel analgesic agents

Shire reports progress of third quarter

Light Sciences Oncology completes enrollment in phase III clinical trial of Litx in HCC

Roche to acquire Memory Pharmaceuticals under definitive merger agreement

H. Lundbeck commences phase II trials for Lu-AE-58054

Valeant reports encouraging 48-week results from phase IIb clinical trial of taribavirin

Protox reports positive results from phase II study of PRX-302 in BPH

Arana commences phase II ART-621 trial in rheumatoid arthritis

FDA issues complete response letter to Johnson & Johnson for ceftobiprole

Amorfix completes ALS drug discovery program with third milestone

MorphoSys and Galapagos to co-develop novel antibodies in bone and joint disease

Pharming presents positive results from phase I Prodarsan study

Provectus enrolls half of patient population in phase II PV-10 melanoma trial

Phase I and preclinical results for anti-HCV agent ANA-598 reported

Japan approves additional indication for Lilly's Gemzar in urothelial cancer

Australian TGA grants orphan drug status to DOR BioPharma's orBec for GI GVHD

Shionogi receives Japanese approval for additional indication for Flomox in adults

Anxiolytic and analgesic profile of NeuroSearch's novel GABA-A receptor positive modulator

Novel promising approach for treating diabetes discovered with JNK inhibition

FDA grants full approval to Pfizer's CCR5 antagonist Selzentry for HIV

Abbott's V1b vasopressin antagonists, effective in models of anxiety and depression

Anti-VEGF agents improve retinopathy of prematurity

Antihypertensive efficacy seen with PS-433540 in double-blind trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...